-
-
In this issue: Anticholinergic drugs for COPD; pioglitazone for diabetes prevention; insulin degludec in Phase 3 trials; and FDA Actions.
-
Exposure to coccidioidomycosis in the laboratory can represent a significant hazard, resulting in serious and even fatal infection. In particular, opening culture plates in the lab, without appropriate precautions, can result in the aerosolization of artificially large numbers of arthroconodia.
-
Due to heightened surveillance of acute febrile illness in China, a severe illness associated with thrombocytopenia and multi-system organ involvement was recognized beginning in 2009.
-
Linezolid is an oxazolidinone agent that has been shown to be effective for the treatment of infections caused by Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
-
Despite the recent gains achieved by multidisciplinary control programs, malaria still kills nearly 1 million people and causes almost 300 million symptomatic illnesses globally each year, with most of this burden borne by sub-Saharan Africa.
-
A study compared culture- and PCR-based bacterial identification methods among 85 children hospitalized at a single medical center with parapneumonic effusion in 2009.
-
-
In this issue: Apixaban and rivaroxaban near approval for nonvalvular atrial fibrillation; fidaxomicin for C. difficile infections; guideline for intensive insulin therapy; and FDA Actions.
-
Community acquired pneumonia "bundles" often include the use of the pneumococcal urinary antigen assay, but how useful is it for streamlining antibacterial use?